The document provides an earnings release and financial highlights for Profarma's 1Q16 results. Some key points include: - Gross revenue increased 16.9% to R$1.338 billion driven by growth across all divisions. - Consolidated EBITDA rose 31.0% to R$25.8 million with an EBITDA margin of 2.2%. - The pharmaceutical distribution division saw a 17.0% revenue increase and 16.5% EBITDA growth. - Specialties revenue grew 38.8% and EBITDA rose 82.9%. - Retail sales increased 12.4% while EBITDA grew 81.7% to R$3.5

1. 1Q16 EARNINGS RELEASE
MAY 5, 2016

2. Highlights | Corporate
2
The only Brazil’s mixed market player that features exposure and expansion capacity
in the segments of Retail, Hospital & Specialties and Distribution;
Strategic partnership with AmerisourceBergen, the world’s largest player in the
pharmaceutical specialties, resulting in the creation of the company Profarma
Specialty;
The Company carried out four acquisitions between 2012-2015, including its entry
into the Retail pharmaceutical segment, and the attainment of a market position as
2nd largest player within this segment in the state of Rio de Janeiro;
Proven capacity to integrate acquisitions, combining all group companies in the SAP
plataform, BI Cognos and Hyperion.

3. Highlights | 1Q16
3
CONSOLIDATED PRO-FORMA
(considering 100% of all companies)
• Gross revenue climbed by 16.9%;;
• Consolidated EBITDA increased by 31.0% to R$ 25.8 million, with
EBITDA margin of 2.2%;
• The consolidated cash cycle was shortened by 1.1 days to 32.9 days;
and;
• The annual price increase, on March 31, came to 11.5% on average
– the highest in the last 14 years – whereas the 2015 increase stood at
5.5%.
RETAIL
• Total sales rose by 12.4%;
• EBITDA increased by 81.7% to R$ 3.5 million, with EBITDA
margin of 1.8%; and
• Operating expenses fell by 0.6 p.p., from 27.2% to 26.5%;
• Average monthly sales per mature store grew by 9.6%.
SPECIALTIES
• The Division’s sales rose by 38.8%;
• EBITDA rose by 82.9% and amounted to R$ 4.4 million, with
EBITDA margin of 2.1%;
• Operating expenses dropped by 1.1 p.p., from 9.8% to 8.3%; and
• Sales to the private sector skyrocketed by 52.4%.
PHARMACEUTICAL DISTRIBUTION
• Sales rose by 17.0%;
• EBITDA rose by 16.5% and amounted to R$ 17.9 million, with
EBITDA margin of 2.0%;
• Operating expenses dropped by 1.1 p.p., from 7.9% to 6.8%; and
• Sales of health & beauty products climbed by 38.8%.

4. Specialties(*) Retail(**) Consolidated (*)(**)Pharmaceutical
Distribution
Highlights | Breakdown by Division – 1Q16
4
Gross Revenues
Gross Profit
SGA
Ebitda
(*) Pro-forma figures: 100% of revenues from Tamoio and Drogasmil / Farmalife in 1Q15.
(**) Pro-forma figures: 100% of revenues from Specialties (1Q15 and 1Q16).
1Q15 1Q16
166.3
18.2
15.0
2.4
230.9
24.1
18.3
4.4
1Q15 1Q16
174.4
51.5
47.4
1.9
195.9
58.0
52.1
3.5
1Q15 1Q16
1,144.8
147.2
121.8
19.7
1,338.2
157.6
130.4
25.8
1Q15 1Q16
873.0
77.5
59.5
15.4
1,021.0
75.4
59.9
17.9

5. CONSOLIDATED PERFORMANCE

6. Specialties
Consolidated Performance
6
Gross Revenues Evolution
(R$ million)
Pharmaceutical Distribution
Sales rose by 17.0% in comparison
with 1Q16.
The Division’s sales rose by 38.8%
year-over-year.
Total sales rose by 12.4% year-over-
year.
Retail
Accounting Consolidated Gross Revenues
Pro-forma Consolidated Gross Revenues: 100% of revenues from
Tamoio (1Q15 and 4Q15) and Specialties
943.5
201.3
1,144.8
1,001.1
277.9
1,279.0
1,126.0
212.2
1,338.2
1Q15 4Q15 1Q16
4.6%
16.9%

7. Performance by Division
Pharmaceutical Distribution Specialties(**) Retail
7
Gross Revenues Evolution
(R$ million)
Accounting Gross Revenues
Pro-forma additional Gross
Revenues
(*) Pro-forma figures: 100% of revenues from Tamoio and Drogasmil / Farmalife
(**) Pro-forma figures: 100% of revenues from Specialties
1Q15 4Q15 1Q16
873.0
955.1
6.9%
17.0%
1Q15 4Q15 1Q16
166.3
224.1
230.9
3.0%
38.8%
1Q15(*) 4Q15(*) 1Q16
72.0
12.4%
102.3
116.3
81.8
174.4
195.9
-1.1%
1,021.0 198.1

8. Consolidated Performance
8
Pro-forma (*)
Gross Profit
(R$ million and % Net Revenues)
(*) Pro-forma figures: 100% of revenues from Tamoio (1Q15 and 4Q15) and Specialties
1Q161Q15 4Q15 1Q161Q15 4Q15
12.1%
99.5
12.2%
105.7
13.6%
133.4
14.4%14.6%
147.2
161.5
13.5%
157.6

9. Consolidated Performance
9
Operating Expenses – SGA
(R$ $ million and % Net Revenues)
Pro-forma (*)
(*) Pro-forma figures: 100% of revenues from Tamoio (1Q15 and 4Q15) and Specialties
12.1%
121.8
12.3%
138.3
11.1%
130.4
82.9
93.4
112.1
10.1%
10.8 %
11.5%
1Q161Q15 4Q15 1Q161Q15 4Q15

10. Consolidated Performance
10
Adjusted EBITDA and Adjusted EBITDA Margin
(R$ million and % Net Revenues)
Pro-forma (*)
(*) Pro-forma figures: 100% of revenues from Tamoio (1Q15 and 4Q15) and Specialties
1.6%
13.5
2.1%
18.0
2.1%
20.7
14.9%
53.8%
2.0%
19.7
2.4%
27.1
2.2%
25.8
-4.8%
31.0%
1Q161Q15 4Q15 1Q161Q15 4Q15

11. Consolidated Performance
11
Net Profit
(R$ million and % Net Revenues)
Pro-forma (*)
1Q15 4Q151Q164Q151Q15 1Q16
(7.3)
(6.0)
-0.6% -0.6%
-0.9%
(6.8)
(10.2)
(7.6)
-0.9% -08% -0.9%
(9.3)
(3.0)
(6.2)(4.4)
-0.4% -0.5% -0.6%
(1.4)
(3.9)
(6.9)
-0.1% -0.3%
-0.6%
Net Profit
Adjusted Net Profit
Pro-Forma Net Profit
Pro-Forma Adjusted Net Profit
(*) Pro-forma figures: 100% of revenues from Tamoio (1Q15 and 4Q15) and Specialties

12. Consolidated Performance
Cash Flow
(R$ million)
Cash Cycle
(Days)
12
Consolidated
Pro-forma
Cash Cycle *
Accounts Receivable¹
Inventories²
Accounts Payable³
Consolidated Pharma PFS. Retail
1Q16
(40.8)
15.8
(56.6)
(40.9)
32.0
(49.7)
1Q15
32.9
9.3
23.6
(7.2)
56.1
81.8
1Q164Q1541Q154
1Q161Q161Q16
44.5
70.2
81.9
32.834.0
45.5
62.7
74.2
43.8
70.7
81.4
33.2
19.3
80.5
62.4
37.441.8
58.8
44.3
61.4
27.9
50.9
60.4
83.4
Cash Flow Generated /
Used) in Operating Activities
Internal Cash Generation
Operating Assets Variation
Cash Flow (Used)
in Investing Activities
Cash Flow Generated /
(Used) by Financing Activities
Net Increase /
(Decrease) in Cash
* Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
(4) The account was based on the average gross sale and CGS, excluding Tamio’s
chain (included in Retail’s Division).

13. Consolidated Performance
13
Capex
(R$ million)
Indebtedness: Net Debt and Net Debt /
EBITDA(R$ million)
IT
Capex
1Q16
Others
Machinery and
Equipment
1Q15 4Q15 1Q16
205.1
3.1x
236.6
3.0x
287.7
3.3x
3.80.5
0.4
2.9

14. PHARMACEUTICAL DISTRIBUTION

15. Pharmaceutical Distribution
Operating expenses
dropped by 1.1 p.p., from
7.9% to 6.8%.
EBITDA rose by 16.5% and
amounted to R$ 17.9 million,
with EBITDA margin of 2.0%;
Sales rose by 17.0%;
15
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
1Q15 1Q161Q15 1Q161Q15 1Q161Q15 1Q16
2.02.0
6.8
7.9
8.6
10.3
1,021.0
873.0

16. SPECIALTIES

17. 17
Specialties
The Division’s sales rose by
38.8%;
EBITDA rose by 82.9% and
amounted to R$ 4.4 million,
with EBITDA margin of 2.1%;
Operating expenses
dropped by 1.1 p.p., from
9.8% to 8.3%; and
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
1Q15 1Q161Q15 1Q161Q15 1Q161Q15 1Q16
2.1
1.6
8.7
9.8
11.4
11.8
230.9
166.3

18. RETAIL

19. 19
Retail
Total sales rose by 12.4%;
Operating expenses fell by
0.6 p.p., from 27.2% to
26.5%;
EBITDA increased by 81.7%
to R$ 3.5 million, with
EBITDA margin of 1.8%;
Financial Data
(R$ million and % Net Revenues)
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
1Q15 1Q161Q15 1Q161Q15 1Q161Q15 1Q16
1.8
1.1
26.6
27.2
29.629.5
195.9
174.4
(*) !Q15 Pro-forma figures: 100% of revenues from Tamoio

20. Retail
20
1Q15 1Q164Q15 1Q15 1Q164Q151Q15 1Q164Q15 1Q15 1Q164Q15
11.3%
9.6%
8.2%
-1.7 p.p.
1.4 p.p.
13.2%
10.6%
548.3
556.5
500.1
9.6%
-1.5%
Total Sales Growth
(%)
SSS Mature Stores
(%)
Same Store Sales
(%)
Monthly Average
Store's Sales
(R$ thousand)
11.9%
11.3%
0.5 p.p.
1.1 p.p.
12.4%
(*) 1Q15 Pro-forma figures: 100% of revenues from Tamoio
11.3%
-1.9 p.p.
0.7 p.p.

21. Retail
21
0 Opening
1 Close-downs
0 Reformulated
105 Mature
1Q15
vs.
1Q16
1Q15 1Q164Q151Q15 4Q15 1Q16
32.34
34.49
32.84
6.6%
5.0%
124
129
128
3.2%
-0.8%
Average Ticket
(in reais)
# of Stores
(units)
(*) !Q15 Pro-forma figures: 100% of revenues from Tamoio

22. ANALYST COVERAGE

23. Analyst Coverage
23
Brasil Plural Guilherme Assis +55 (11) 3206-8285 guilherme.assis@brasilplural.com.br
BTG Pactual Rodrigo Gastim +55 (11) 3383-2468 rodrigo.gastim@btgpactual.com
BofA Merrill Lynch Roberto Otero +55 (11) 2188-4119 roberto.otero@baml.com
Morgan Stanley Javier Martinez de Olcoz +55 (11) 3048-6088 javier.martinez.olcoz@morganstanley.com
Votorantim Andre Parize +55 (11) 5171- 5870 andre.parize@votorantimcorretora.com.br
J.P. Morgan Joseph Giordano +55 (11) 4950-3020 joseph.giordano@jpmresearchmail.com
Company Analyst Telephone E-mail

24. Max Fischer - CFO e IRO & Beatriz Diez - IRM
www.profarma.com.br/ir | Phone.: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br